Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Corporate Update

MarketWire Canada January 5, 2017

Hemostemix Announces Reorganization

MarketWire Canada December 22, 2016

Hemostemix Inc.: Early Warning Report Issued Pursuant to National Instrument 62-103

MarketWire Canada November 2, 2016

Hemostemix Granted Two Additional Patents in the US and in Canada

MarketWire Canada October 3, 2016

Hemostemix Announces Offering

MarketWire Canada September 22, 2016

Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility

MarketWire Canada September 21, 2016

Hemostemix Announces Results of Annual and Special Meeting

MarketWire Canada September 9, 2016

Hemostemix Closes $1,644,000 Offering

MarketWire Canada September 2, 2016

Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board

MarketWire Canada September 1, 2016

Hemostemix Voids Taiwanese Agreement

MarketWire Canada August 29, 2016

Hemostemix Issues Letter to Shareholders Urging Them to Vote Their WHITE Proxy

MarketWire Canada August 29, 2016

Hemostemix Announces Corporate Updates

MarketWire Canada June 28, 2016

Hemostemix Announces Non-Brokered Private Placement

Marketwired April 20, 2016

Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles

Marketwired April 18, 2016

Hemostemix Appoints Robert Achtymichuk as Vice President, Business Development

Marketwired March 31, 2016

Hemostemix Appoints Hardean E. Achneck, M.D. as Chief Medical Officer

Marketwired March 25, 2016

Hemostemix Issues Corporate Update From CEO Elmar Burchardt

Marketwired February 3, 2016

Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program

Marketwired January 21, 2016

Hemostemix to Present at Phacilitate Cell & Gene Therapy World 2016

Marketwired January 21, 2016

Hemostemix Joins the OTCQX Marketplace in the United States

Marketwired December 28, 2015